Results

Total Results: 1,134 records

Showing results for "days".

161. Outcome Measure Harmonization and Data Infrastructure for Patient-Centered Outcomes Research in Depression: Final Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/outcome-research-white-paper.pdf
     June 01, 2022 - half the days, and Nearly every day. … Frequency over the past 2 weeks (once, several days, more than half the days, nearly every day) b. … Timeframe for measurement: ● 6 months (+/- 60 days) ● 12 months (+/- 60 days) In some implementations … Timeframe for measurement: ● 6 months (+/- 60 days) ● 12 months (+/- 60 days) In some implementations … Timeframe for measurement: ● 6 months (+/- 60 days) ● 12 months (+/- 60 days) In some implementations

162. Version 2_Risk of Reinfection From SARS-CoV-2 -- An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-2-risk-of-reinfection-from-SARSCoV2_0.pdf
     December 31, 2022 - of followup compared with 4.25 to 5.92 per 100,000 person-days in the younger age groups. … that 4 per 1,000 individuals who had an initially positive PCR had another positive PCR 90 or more days … at least two negative PCRs, and then a positive PCR test at least 90 13 days … the point of care test and ELISA at baseline, 1 month, 5 months; reinfection rate at 180 and 360 days … Establishment of a clinical (12 months) and biological (15 days) basis for to describe the number

163. Peripheral Nerve Blocks for Postoperative Pain Management in Cardiothoracic Surgery (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-nerve-block-protocol.pdf
     November 18, 2023 - findings vary by baseline patient clinical characteristics (e.g., ASA status, chronic opioids (>90 days … /adverse events of treatment (nerve damage, bleeding, all- cause return to ED/hospital within 30 days … ; 30 days up to ≤3 months Post-operative period 3-12 months  Other timing Setting   Perioperative … /ethnicity, sex, BMI, ADA status, pre-existing psychiatric diagnosis, and chronic opioid use (>90 days … This can be left in place for up to seven days.

164. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
     January 01, 2025 - Baseline: 1,514 4-year followup: 1,217 Groups unclear A: Self-reported frequent cannabis use (≥20 days … use of Strainprint app (tracking app used to obtain data on medicinal cannabis use): 31 weeks (214 days

165. App-F1-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
     May 29, 2025 - NPP_Pain Table F-1a. Pain severity for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (Wk) Time Category Grp 1 Baseline N Grp 1 Baseline Mean Pain Score Grp1 Baseline Variance Type Grp1 Baseline Variance Grp1 Baseline Lower Limi…

166. Prehospital EMS Blood Transfusion and Fluid Interventions for Hemorrhagic Shock (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ems-blood-transfusion-protocol.pdf
     September 24, 2024 - We will exclude studies reporting outcomes beyond 30 days post-injury, since multiple other factors … /survival o To arrival at hospital o To hospital discharge o Any period less than or equal to 30 days … Extended, Modified Rankin Scale, Cerebral Performance Category • Length of stay o Hospital free days … o ICU free days Intermediate Outcomes in the prehospital or ED setting • Physiological indicators … solution combined with blood • Cost-effectiveness, other outcomes Timing • Outcomes up to 30 days

167. App-E-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
     May 29, 2025 - NPP Table E-1. Neuropathic pain study characteristics Author, Year Country Trial Type Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed Intervention Duration (Weeks) Funding Source Hussain, 2021 Pakistan Placebo-controlled Fair NPP (DPN) Age, mean: 45 Female: 0% R…

168. Comparative Effectiveness of β-Adrenergic Antagonists on the Risk of Rehospitalization in Adults with Heart Failure (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-rehospitalization_research.pdf
     November 01, 2007 - If the refill interval was more than 14 days, then the individual was considered off β-blocker therapy … We also classified the total duration (in days) of exposure to each of the different β- blockers during … In addition, for each of the different β-blockers, we calculated the proportion of days covered after … range 2 to 5 days). … HPHC) Medications within 30 days before admission, N (%) β-blockers Acebutolol 7 (0.1) 6

169. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/11_peptic_ulcer_potential_high_impact_2012-12-111.pdf
     January 01, 2012 - If the patient does not improve after 3–5 days, colectomy (i.e., surgical removal of the colon) can … (1–5 days). … of treatment, 54% of patients treated with teduglutide were able to reduce the number of infusion days … per week by 1 or more days, compared with 23% of patients treated with placebo (p=0.005). 57 … per week, and 24% of patients reduced their infusion days per week by 3 or more days.

170. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/c-difficile-future_research.pdf
     October 26, 2012 - No significant differences in outcomes, including initial cure, clinical recurrence, and mean days to … resolution of diarrhea at end of treatment (~10 days), harms, recent antibiotic history; secondary … No significant differences in outcomes, including initial cure, clinical recurrence, and mean days to … All teleconference call materials were distributed a few days prior to scheduled calls. … No significant differences in outcomes, including initial cure, clinical recurrence, and mean days to

171. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - , rifaximin’s FDA-approved labeling recommends one 550 mg tablet, taken 3 times per day, for 14 days … for 42 tablets at a dose of 550 mg each, which is enough for a recommended treatment course over 14 days … IBS, rifaximin’s labeled, recommended dosage is one 550 mg tablet, taken 3 times per day, for 14 days … of 30% or more in mean weekly pain score and a decrease of 50% or more from baseline in number of days … they would not have the benefit of the medication, they would be sicker and more prone to losing days

172. Outcome Measure Framework Design Document (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/registry-of-patient-registries_research-2014.pdf
     January 01, 2014 - may use the same definition of heart failure, but one registry may collect readmissions within 45 days … of the initial hospitalization, while the other registry collects readmissions within 30 days of the … specified follow-up period or measured over time (e.g., change in blood pressure from baseline to 60 days … period that were followed by an acute readmission for any diagnosis from any hospital within 30 days … The number of acute inpatient stays that are admitted within 30 days of a prior acute discharge

173. TND-555-09-03-2013 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-555-09-03-2013.pdf
     January 01, 2013 - TND-555-09-03-2013 Topic Number(s): 0472 Document Completion Date: 02-13-2013 1 Results of Topic Selection Process & Next Steps  The topic, Behavioral Health Programs for Gestational, Type 1 DM and Type 2 Diabetes Mellitus, will go forward for refinement as an update to or expansion of an exis…

174. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - and 52% of the 0.10-mg/kg/d dose group had a ≥20% reduction in PN, with a reduction of 1 or more days … 24 weeks of treatment, 53.8% of patients treated with teduglutide reduced the number of infusion days … per week by 1 or more days, compared with 23.1% of patients treated with placebo experiencing such … Additionally, after 12 months of teduglutide treatment, 53% of patients reduced their infusion days … per week and 24% of patients reduced their infusion days per week by 3 or more days.

175. S158 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s158.pdf
     October 01, 2007 - Eligible individuals were those who filled a prescription for any drug within 120 days before hospitalization … and another prescription more than 365 days before hospitalization. … Covariates were assessed during the 365 days before hospitalization. … subjects we extracted the fol- lowing variables: age, sex, race, all prescriptions filled within 120 days … The time until death or 365 days of follow-up (whichever came first) was assessed starting from the date

176. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/alcohol-pharma-final-protocol.pdf
     January 01, 2023 - over 1 year, the remaining 4 nonabstinent individuals showed substantial decreases in drinking days … Consumption outcomes  abstinence/any drinking - rates of continuous abstinence - percentage of days … - time to heavy drinking/relapse  reduction in alcohol consumption - number of heavy drinking days … - percentage of subjects with no heavy drinking days - number of drinking days - drinks per drinking … use random-effects models to estimate pooled effects.50 For continuous outcomes (e.g., percentage of days

177. Making Healthcare Safer IV_Rapid Response: Use of Report Cards and Outcome Measurements To Improve the Safety of Surgical Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs-IV-rapid-response-surgical-report-cards.pdf
     November 01, 2023 - estimated to increase hospitalization costs by more than $20,000 per admission and extends LOS by 9.7 days … by bacteremia.40,41 Following colorectal surgery, anastomotic leaks incurred additional LOS of 7.3 days … and hospital costs of $24,129.42 Postoperative respiratory complications increase LOS by 5 days on … details, immediate postoperative hospitalization details, adverse events or complications within 90 days … Report decrease catheter infections (5.5/1000 catheter days to 1.7/1000 catheter days) and decrease

178. Management and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/binge-eating_clinician.pdf
     May 01, 2016 - . ��� 3 966 Lisdexamfetamine decreased binge-eating days per week, weight, and eating- related obsessions … ; 95% CI -1.26 to -0.09). ��� 3 (MAc) 122 Antidepressants decreased the frequency of binge-eating days … At least 2 days a week for 6 months (DSM-IV frequency and duration criteria) b.

179. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotics-children-update_research-protocol.pdf
     December 04, 2015 - Substance use disorder: cravings, abstinence/substance use days*; ◦!

180. Fagerlin-notes-151007 copy-Teresa (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/fagerlin-presentation.pdf
     May 29, 2025 - Well, even  with  that and  calling them a couple days before the visit and  reminding them to … The default was after three days the catheter was to be removed  unless indicated  otherwise; and